AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16122458 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 201
Study 16122458 — intervention group
Group type: COMPARATOR
Intervention: Traditional electrocautery and scissors
Number of subjects: 201
Study 12588088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher toenail selenium concentrations (at the 75th percentile)
Number of subjects: 500
Study 12588088 — intervention group
Group type: COMPARATOR
Intervention: Low toenail selenium concentrations (lowest levels)
Number of subjects: 500
Study 10080585 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 months of chemotherapy with irradiation (XRT) of the primary site; 7 patients
Number of subjects: 31
Study 10080585 — intervention group
Group type: COMPARATOR
Intervention: 8 months of chemotherapy without XRT; 4 patients
Number of subjects: 31
Study 10080585 — intervention group
Group type: COMPARATOR
Intervention: 9 weeks of chemotherapy without XRT; 20 patients
Number of subjects: 31
Study 8622038 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (5 to 15 micrograms/kg/d subcutaneously)
Number of subjects: 37
Study 8622038 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 37
Study 8622038 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 37
Study 10149499 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 21
Study 10149499 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrafiltration
Number of subjects: 21
Study 10149499 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 6130329 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostacyclin, PGI2) infusion at 7.5 ng/kg/min after the first hour for 5 hours, administered weekly for three weeks.
Number of subjects: 14
Study 6130329 — intervention group
Group type: COMPARATOR
Intervention: Buffer infusion (control group) for 5 hours, administered weekly for three weeks.
Number of subjects: 14
Study 6130329 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostacyclin, PGI2) infusion.
Number of subjects: 14
Study 31141195 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral treatment (ART) within 14 days
Number of subjects: 75
Study 31141195 — intervention group
Group type: COMPARATOR
Intervention: Delayed initiation of antiretroviral treatment (ART) after nutritional recovery
Number of subjects: 75
Study 29916324 — intervention group
Group type: EXPERIMENTAL
Intervention: Orem's self-care model
Number of subjects: 0
Study 29916324 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 27155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt abdominal entry
Number of subjects: 13153
Study 27155903 — intervention group
Group type: COMPARATOR
Intervention: Sharp abdominal entry
Number of subjects: 13153
Study 27155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorisation of the uterus for repair
Number of subjects: 13153
Study 27155903 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal repair
Number of subjects: 13153
Study 27155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer closure of the uterus
Number of subjects: 13153
Study 27155903 — intervention group
Group type: COMPARATOR
Intervention: Double layer closure of the uterus
Number of subjects: 13153
Study 27155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 13153
Study 27155903 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of the peritoneum
Number of subjects: 13153
Study 27155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromic catgut sutures
Number of subjects: 13153
Study 27155903 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin-910 sutures
Number of subjects: 13153
Study 24786016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous (SC) injection of 12.5 mg rhTNFR-Fc
Number of subjects: 40
Study 24786016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous (SC) injection of 25 mg rhTNFR-Fc
Number of subjects: 40
Study 24786016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous (SC) injection of 50 mg rhTNFR-Fc
Number of subjects: 40
Study 24786016 — intervention group
Group type: EXPERIMENTAL
Intervention: Six SC injections of 25 mg rhTNFR-Fc once every 3 days
Number of subjects: 40
Study 24786016 — intervention group
Group type: COMPARATOR
Intervention: Healthy Chinese subjects (control)
Number of subjects: 40
Study 23006933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sericin cream
Number of subjects: 50
Study 23006933 — intervention group
Group type: COMPARATOR
Intervention: Cream base (placebo)
Number of subjects: 50
Study 20329659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (test formulation, 250 mg/5 mL suspension)
Number of subjects: 0
Study 20329659 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of cefuroxime axetil
Number of subjects: 0
Study 17545874 — intervention group
Group type: EXPERIMENTAL
Intervention: Videostroboscopy (VS)
Number of subjects: 162
Study 17545874 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed glottography (HGG)
Number of subjects: 162
Study 16364124 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanol-based hand rub with emollients (0.81%, w/w)
Number of subjects: 35
Study 16364124 — intervention group
Group type: COMPARATOR
Intervention: Propanol-based hand rub without emollients
Number of subjects: 35
Study 11899906 — intervention group
Group type: EXPERIMENTAL
Intervention: Various dose-fractionation schedules for palliative radiotherapy
Number of subjects: 1200
Study 9620101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 180
Study 9620101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 180
Study 9620101 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 180
Study 8553306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg/day for 15 days and then tapering off)
Number of subjects: 117
Study 8553306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 2096210 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 2096210 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 21
Study 92589 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with lipocaine or trimecaine (antiarrhythmic drugs)
Number of subjects: 209
Study 92589 — intervention group
Group type: COMPARATOR
Intervention: Control group (random control group)
Number of subjects: 209
Study 30510079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (900 mg every 8 weeks)
Number of subjects: 195
Study 30510079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 195
Study 30510079 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (900 mg every 2 weeks)
Number of subjects: 195
Study 30510079 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 195
Study 28433518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 10 mg/kg
Number of subjects: 50
Study 28433518 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 20 mL
Number of subjects: 50
Study 25904685 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA+MMA
Number of subjects: 10
Study 25904685 — intervention group
Group type: COMPARATOR
Intervention: HCA
Number of subjects: 10
Study 25904685 — intervention group
Group type: COMPARATOR
Intervention: MMA
Number of subjects: 10
Study 24050582 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-supplemented hemp seed and evening primrose oils with advised Hot-nature diet
Number of subjects: 100
Study 24050582 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-supplemented hemp seed and evening primrose oils
Number of subjects: 100
Study 24050582 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 100
Study 22220458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliative glaucoma
Number of subjects: 129
Study 22220458 — intervention group
Group type: EXPERIMENTAL
Intervention: Open angle glaucoma
Number of subjects: 129
Study 22220458 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 129
Study 18302020 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and docetaxel
Number of subjects: 708
Study 18302020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 708
Study 17045903 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus training in physical counterpressure maneuvers (PCM)
Number of subjects: 223
Study 17045903 — intervention group
Group type: COMPARATOR
Intervention: Standardized conventional therapy alone
Number of subjects: 223
Study 15613917 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 40
Study 15613917 — intervention group
Group type: COMPARATOR
Intervention: 250 mg aspartame (control test)
Number of subjects: 40
Study 10775738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg oral micronized 17beta‐E2
Number of subjects: 333
Study 10775738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral micronized 17beta‐E2
Number of subjects: 333
Study 10775738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral micronized 17beta‐E2
Number of subjects: 333
Study 10775738 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral micronized 17beta‐E2
Number of subjects: 333
Study 10775738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 9369050 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg i.m.
Number of subjects: 100
Study 9369050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg orally
Number of subjects: 100
Study 9369050 — intervention group
Group type: COMPARATOR
Intervention: Control group (Atropine 0.5 mg i.m.)
Number of subjects: 100
Study 9369050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg i.m.
Number of subjects: 100
Study 7690689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentastarch
Number of subjects: 41
Study 7690689 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 41
Study 3755561 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml 0.5% hyperbaric tetracaine
Number of subjects: 40
Study 3755561 — intervention group
Group type: COMPARATOR
Intervention: 3 ml 0.5% hyperbaric bupivacaine
Number of subjects: 40
Study 29864467 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hydrogen peroxide topical solution (HP40)
Number of subjects: 937
Study 29864467 — intervention group
Group type: COMPARATOR
Intervention: vehicle (control)
Number of subjects: 937
Study 26569059 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly methotrexate (MTX)
Number of subjects: 210
Study 26569059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Number of subjects: 210
Study 26569059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined predictive groups from both arms
Number of subjects: 210
Study 23981346 — intervention group
Group type: EXPERIMENTAL
Intervention: 130% of Pmax
Number of subjects: 12
Study 23981346 — intervention group
Group type: EXPERIMENTAL
Intervention: All loading protocols
Number of subjects: 12
Study 23981346 — intervention group
Group type: COMPARATOR
Intervention: Control (without extra load)
Number of subjects: 12
Study 22789134 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of pumactant
Number of subjects: 134
Study 22789134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carbon dioxide)
Number of subjects: 134
Study 22789134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pumactant and placebo)
Number of subjects: 134
Study 20561836 — intervention group
Group type: EXPERIMENTAL
Intervention: Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management (6-week program)
Number of subjects: 42
Study 20561836 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study 18756871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilio-inguinal blockade before surgical incision
Number of subjects: 60
Study 18756871 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration after closing the aponeurosis
Number of subjects: 60
Study 18756871 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic infiltration (Control group III)
Number of subjects: 60
Study 15756212 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year
Number of subjects: 18
Study 15756212 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year followed by a second year of GH
Number of subjects: 18
Study 15756212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH for 1 year)
Number of subjects: 18
Study 14620312 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study 14620312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 50
Study 10500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg/q12hr)
Number of subjects: 174
Study 10500313 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (target aPTT: 55‐85 sec)
Number of subjects: 174
Study 10500313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study 8926771 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-infected women
Number of subjects: 528
Study 8926771 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of cervical lesions
Number of subjects: 528
Study 1825737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg/day)
Number of subjects: 9
Study 1825737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6361991 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion
Number of subjects: 39
Study 6361991 — intervention group
Group type: COMPARATOR
Intervention: No granulocyte transfusion (Control)
Number of subjects: 39
Study 31138501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard femoral components
Number of subjects: 271
Study 31138501 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow femoral components
Number of subjects: 271
Study 31138501 — intervention group
Group type: EXPERIMENTAL
Intervention: All systems
Number of subjects: 271
Study 28049010 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour bladder health class
Number of subjects: 647
Study 28049010 — intervention group
Group type: COMPARATOR
Intervention: 20-minute abbreviated class video
Number of subjects: 647
Study 24963912 — intervention group
Group type: EXPERIMENTAL
Intervention: ARME appliance
Number of subjects: 21
Study 24668250 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Gy single dose
Number of subjects: 457
Study 24668250 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 Gy single dose
Number of subjects: 457
Study 22926599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 0.5 mg/kg per day for 1 week, followed by 1.2 mg/kg per day for 7 weeks
Number of subjects: 128
Study 22926599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128
Study 22926599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 19398192 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 400
Study 19398192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 400
Study 19398192 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 400
Study 16860259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 891
Study 16860259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea + Pioglitazone (SU + PIO)
Number of subjects: 891
Study 16860259 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Pioglitazone (MET + PIO)
Number of subjects: 891
Study 16860259 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 891
Study 15113713 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (2.8 g DHA/d)
Number of subjects: 32
Study 11355946 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose FEC (5 adjuvant courses of 5-FU, epirubicin, and cyclophosphamide)
Number of subjects: 33
Study 11355946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBSCT (4 x FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin, and autologous PBSCT)
Number of subjects: 33
Study 11355946 — intervention group
Group type: COMPARATOR
Intervention: Both standard-dose and high-dose chemotherapy
Number of subjects: 33
Study 11355946 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patients post-treatment
Number of subjects: 33
Study 11355946 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity
Number of subjects: 33
Study 9120586 — intervention group
Group type: EXPERIMENTAL
Intervention: Unperturbed trials
Number of subjects: 0
Study 9120586 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed trials
Number of subjects: 0
Study 8172356 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with a purified standardized preparation of Dermatophagoides farinae for 12 months
Number of subjects: 31
Study 8172356 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 31
Study 8172356 — intervention group
Group type: COMPARATOR
Intervention: Open control group
Number of subjects: 31
Study 2971185 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41740 (two tablets per day for one week during the first month and one tablet per day for one week during the second and third months)
Number of subjects: 0
Study 2971185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31885114 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized simulations embedded in pedagogically supportive activities (n = 40)
Number of subjects: 85
Study 31885114 — intervention group
Group type: COMPARATOR
Intervention: Routine face-to-face follow-up (Control group, n = 45)
Number of subjects: 85
Study 31230495 — intervention group
Group type: EXPERIMENTAL
Intervention: EnHAp (nanohydroxyapatite synthesized from eggshell waste)
Number of subjects: 25
Study 31230495 — intervention group
Group type: COMPARATOR
Intervention: Colgate Sensitive
Number of subjects: 25
Study 31230495 — intervention group
Group type: COMPARATOR
Intervention: Eggshell powder alone
Number of subjects: 25
Study 31230495 — intervention group
Group type: COMPARATOR
Intervention: Calcined eggshell powder
Number of subjects: 25
Study 31230495 — intervention group
Group type: COMPARATOR
Intervention: Calcium dihydrogen phosphate
Number of subjects: 25
Study 28674113 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium animalis subsp lactis and Lactobacillus rhamnosus)
Number of subjects: 290
Study 28674113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 26461100 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor‐Assisted Problem‐Solving (CAPS)
Number of subjects: 132
Study 26461100 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study 24315255 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CES device
Number of subjects: 0
Study 24315255 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study 24315255 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (UC)
Number of subjects: 0
Study 21715517 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril or Losartan
Number of subjects: 223
Study 21715517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 17980009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 22
Study 17980009 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 22
Study 16516598 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 74
Study 16516598 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for heart failure
Number of subjects: 74
Study 15281476 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (Pulmicort Respules)
Number of subjects: 2356
Study 15281476 — intervention group
Group type: COMPARATOR
Intervention: Reference treatments
Number of subjects: 2356
Study 12374901 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg)
Number of subjects: 345
Study 9818697 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Number of subjects: 70
Study 9818697 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Number of subjects: 70
Study 7536271 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil alone
Number of subjects: 50
Study 7536271 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus alpha-interferon
Number of subjects: 50
Study 7536271 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil alone and with alpha-interferon
Number of subjects: 50
Study 2527239 — intervention group
Group type: EXPERIMENTAL
Intervention: Farlutal (500 mg MPA tablets, twice daily for 20 days)
Number of subjects: 16
Study 2527239 — intervention group
Group type: COMPARATOR
Intervention: Clinovir (500 mg MPA tablets, twice daily for 20 days)
Number of subjects: 16
Study 4624595 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate administered 20 minutes before exercise
Number of subjects: 10
Study 4624595 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate administered immediately before exercise
Number of subjects: 10
Study 4624595 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate administered at the end of exercise
Number of subjects: 10
Study 4624595 — intervention group
Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 10
Study 30352271 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE reporting workflow
Number of subjects: 20
Study 30352271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 20
Study 30352271 — intervention group
Group type: COMPARATOR
Intervention: Osirix®
Number of subjects: 20